<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Genetic Engineering News | Biodesix

The use of Biodesix’ predictive cancer therapy assay VeriStrat has been validated in a Phase III trial originally carried out to evaluate GlaxoSmithKline’s Tykerb®/Tyverb® (lapatinib) as an addition to Novartis’ Femara® (letrozole) in breast cancer patients. Data from the trial demonstrated that VeriStrat could be used to identify a group of patients with worse progression-free survival (PFS) when treated with Femara alone, independent of Her2 status.

VeriStrat is a serum proteomic test currently used to identify NSCLC patients who are likely to respond well, or poorly, to treatment using EGFR inhibitors. The Phase III Tykerb trial (designated EGF30008), was the first to evaluate VeriStat in breast cancer and also the first to assess the assay with an endocrine agent, Biodesix notes.

Read more at Genetic Engineering News.

Topics: blood-based cancer test, cancer diagnostics, EGFR, personalized medicine, serum protein test, Veristrat, lapatinib, letrozole, liquid biopsy, NSCLC, oncology, In the News